Targeted therapies in breast cancer:New challenges to fight against resistance

作     者：Viviana Masoud Gilles Pagès 

作者机构：University Nice Sophia AntipolisInstitute for Research on Cancer and Aging of Nice CNRS UMR7284/INSERM U 1081 

出 版 物：《World Journal of Clinical Oncology》 (世界临床肿瘤学杂志（英文版）)

年 卷 期：2017年第8卷第2期

页      面：120-134页

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

基　　金：Supported by The French Association for Cancer Research(ARC) the Fondation de France the French National Institute for Cancer Research(INCA) the Fondation Estée Lauder(Pink Ribbon Award) Roche France and"Cordon de Vie"Monaco 

主　　题：Breast cancers Resistance Human epidermal growth factor receptor 2 Angiogenesis Triple negative Immune tolerance 

摘      要：Breast cancer is the most common type of cancer found in women and today represents a significant challenge to public health. With the latest breakthroughs in molecular biology and immunotherapy, very specific targeted therapies have been tailored to the specific pathophysiology of different types of breast cancers. These recent developments have contributed to a more efficient and specific treatment protocol in breast cancer patients. However, the main challenge to be further investigated still remains the emergence of therapeutic resistance mechanisms, which develop soon after the onset of therapy and need urgent attention and further elucidation. What are the recent emerging molecular resistance mechanisms in breast cancer targeted therapy and what are the best strategies to apply in order to circumvent this important obstacle? The main scope of this review is to provide a thorough update of recent developments in the field and discuss future prospects for preventing resistance mechanisms in the quest to increase overall survival of patients suffering from the disease.